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Abstract
Background Decentralisation of healthcare budgets and issuance of local guidelines means that the use of biosimilars can 
vary by region within a particular country, for example between the 21 counties of Sweden.
Objectives This study aimed to analyse the county-level market dynamics of biosimilar and originator infliximab, which are hos-
pital products, and to examine how local policy measures and practices, in addition to national policy, influenced market dynamics.
Methods We first conducted a literature review on (biosimilar) policies in Sweden, then analysed market data provided by 
IQVIA™ on uptake of originator and biosimilar infliximab within the different counties (Q2 2012 to Q4 2017), including 
discounts from (tender) contracts. Biosimilar market shares were calculated with volume data (measured as defined daily 
doses [DDDs]). We then discussed our findings in semi-structured interviews with the national pricing and reimbursement 
agency, key experts within the county councils of Skåne, Västra Götaland, and Stockholm, and an industry representative.
Results Market shares of biosimilar infliximab vary widely between counties (range 18–96% in 2017). The initial uptake of 
biosimilar infliximab was slow and variable, with abrupt increments in biosimilar market shares coinciding with expiration 
of contracts for the originator product. Different approaches taken by counties to achieve a low cost per DDD of infliximab 
were identified, i.e., a rapid switch to the biosimilar (Skåne), a delayed switch to the biosimilar (Stockholm), or no switch to 
the biosimilar when a favourable price on the originator product could be obtained (Västra Götaland). Quantitative analysis 
showed that 59% of the variability in biosimilar market shares could be explained by the relative difference in discounted 
price between the biosimilar and the originator product. In addition, qualitative analysis indicated the presence of key opinion 
leaders, local guidelines and initiatives, and whose budget it affects as drivers in the decision-making process.
Conclusions Variations in the market share of biosimilar infliximab between the Swedish counties is largely explained by 
the discounted price difference between biosimilar and originator product, and counties used different strategies to leverage 
such biosimilar competition. Additionally, the presence of key opinion leaders, local guidelines and gainsharing arrangements 
appeared to play a role in infliximab market dynamics in counties.
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Key Points 
Biosimilar infliximab market shares in Swedish counties 
ranged from 18 to 96% in 2017.
Variations in the discounted price difference between the 
biosimilar and originator product, and associated savings, 
explain variations in biosimilar uptake between counties.
Counties employ different strategies to achieve low costs 
for treatment with infliximab.
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1 Introduction
The advent of biological medicinal products, i.e. medi-
cines produced by or extracted from a biological source, 
has revolutionised the treatment of many diseases by their 
specificity to key disease mediators, e.g., tumour necro-
sis factor (TNF)-α, a cytokine involved in the body’s 
inflammatory response [1]. Elevated levels of TNFα are 
associated with diseases such as rheumatoid arthritis, 
psoriatic arthritis, ankylosing spondylitis, psoriasis and 
inflammatory bowel disease [2]. Therefore, TNFα inhibi-
tors, medicines that block the activity of TNFα, improved 
the treatment options for these diseases by reducing the 
inflammatory reaction. Currently, five different molecules 
have been proven to inhibit the action of TNFα: infliximab, 
etanercept, adalimumab, certolizumab pegol, and goli-
mumab. In 2017, these molecules had combined global 
sales of $US39.8 billion [3].
However, as patents and other exclusivity rights on 
marketed TNFα inhibitors expire, non-innovator versions, 
i.e., biosimilars, may enter the market. The introduction of 
biosimilars may create competition in this class, possibly 
resulting in lowered prices, and alter market dynamics in 
disease areas using TNFα inhibitors.
In 2013, the first biosimilar of a TNFα inhibitor, bio-
similar infliximab, received marketing authorisation across 
Europe under the names  Inflectra® and  Remsima® [4]. Its 
originator product,  Remicade®, was then one of the top 
three-selling biological products in the world [5]. Market-
ing authorisation for other biosimilars to infliximab fol-
lowed in 2016 with  Flixabi® and in 2018 with  Zessly®. 
Etanercept biosimilars  Benepali® and  Erelzi® received 
marketing authorisation in 2016 and 2017, respectively. 
Several biosimilars to  Humira® (adalimumab) have also 
gained marketing authorisation. Market exclusivity rights 
on the originator product expired in October 2018.
After marketing authorisation is received from the 
European Commission, it is the responsibility of the 
Member States to coordinate pricing, reimbursement and 
subsequent entry of these products to the market. This 
contributes to variations in the use of biosimilars across 
Europe [6]. Furthermore, regional differences in the use 
of medicines can be observed within a country [7–14]; 
for example, in Sweden, the Health and Medical Services 
Act of 1982 (updated in 2017) decentralised responsibili-
ties for healthcare budgets and services to the 21 county 
councils [15, 16]. It was believed that decentralisation of 
the drug budget to the county councils would increase cost 
awareness and improve rational prescribing of medicines 
[17]. By law, the 21 county councils are required to have 
a drug and therapeutics committee, which aims to improve 
rational prescribing of medicines [18]. These drug and 
therapeutics committees are supported by different ther-
apy groups or expert committees and are responsible for 
making recommendations on the use of medicines, includ-
ing advice on purchasing of medicines and education of 
healthcare professionals [19]. Although legislation, gen-
eral health policy objectives, and high-level recommenda-
tions on healthcare are decided at a national level, other 
factors (e.g. local tendering, regional recommendations) 
appear to play a role in the fragmented picture of market 
access of biosimilars in these counties and may explain 
regional variations in biosimilar prices and market shares.
The hospital setting (e.g., infliximab) and outpatient set-
ting (e.g., etanercept) are organised differently in Sweden 
(Fig. 1), providing us the opportunity to distinguish between 
characteristics of the setting and general driving factors that 
influence market dynamics. For medicines administered in 
the hospital setting, public procurement is carried out at the 
county level. The county councils finance these medicines 
and provide recommendations on preferred treatments [20]. 
However, in special cases, the New Therapies Council can 
make recommendations at a national level to pursue equal 
treatment between the counties [21]. On the other hand, in 
the outpatient setting, decisions on pricing and reimburse-
ment of prescription medicines are made by the Dental and 
Pharmaceutical Benefits Agency, a governmental agency 
under the Ministry of Health and Social Affairs [22].
The aim of this study was to both quantitatively and 
qualitatively analyse the market dynamics of biosimilar and 
originator TNFα inhibitors in Sweden’s 21 counties and to 
examine how local policy measures and practices, in addition 
to national policy, influence market dynamics between the 
counties. This article is the first of two and studies regional 
variations in originator and biosimilar infliximab (hospital set-
ting); the second article will discuss the market dynamics of 
originator and biosimilar etanercept (outpatient setting) [45].
2  Methods
A comparative analysis was performed in three steps: (1) 
a review of the literature on (biosimilar) policies in Swe-
den; (2) a comparative analysis of counties’ originator and 
biosimilar infliximab market shares on the one hand, and of 
policy measures and initiatives at national and county levels 
on the other hand; and (3) a discussion of findings via follow-
up interviews with key experts in a selection of counties.
2.1  Literature Review
The literature review served to describe the main character-
istics of the Swedish national healthcare system and policies 
on biosimilars, including county-level policy measures and 
initiatives. We searched PubMed to the end of November 
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2017 by combining search terms on health policy, biosimi-
lars and Sweden. Studies could be published in English, 
Swedish, or Dutch. We also searched the reference lists of 
identified articles for other relevant studies. Articles and 
reports known to the authors were also included. The web-
sites of the county councils and the Dental and Pharma-
ceutical Benefits Agency served as additional information 
sources.
2.2  Analysis of Market Data
Market data on the uptake of originator and biosimilar inf-
liximab in each county were provided by IQVIA™, and 
consisted of units, defined daily doses (DDDs), expenditure 
based on pharmacies’ purchase prices (prices at wholesale 
level) and expenditure based on discounted prices (hospital 
products) on different pack sizes of originator and biosimilar 
infliximab from quarter two of 2012 to quarter four of 2017 
[23]. Net expenditure including discounts from (tender) con-
tracts were used to make calculations on discounted prices 
per DDD. Per county, graphs were drafted to show the evo-
lution in volume (measured as DDDs) and price (measured 
as discounted price per DDD) over time for each origina-
tor and biosimilar product. In this way, the influence of the 
introduction of a biosimilar TNFα inhibitor (i.e., biosimilar 
infliximab) on the originator product could be studied in the 
context of existing policy measures. Biosimilar market shares 
(calculated as volume of biosimilars over volume of biosimi-
lars and originator product) were also determined over time 
for the different counties. Economic theory suggests that a 
lower price will lead to increased uptake of a product. There-
fore, we conducted a simple regression analysis using SPSS 
software [24] to test how much of the variation in biosimilar 
market shares between the counties could be explained by the 
relative difference in discounted price between the biosimilar 
and the originator product. A level of significance of 0.05 
was adopted. Data for 2017 were used in the analysis rather 
than only quarter four of 2017 (most recent data), since the 
data set for 2017 showed more variation in biosimilar mar-
ket shares (2017: 18–96% vs. Q4 2017: 23–94% biosimilar 
market share). Data from earlier than 2017 were not analysed 
because they might reflect a still-developing market. We 
assumed that the prevalence of conditions for which TNFα 
inhibitors were used was the same in all counties [7]. Various 
multiple regression models were used to study the relation 
between the biosimilar market share and various covariates, 
including the number of inhabitants per county, the number 
of inhabitants per procurement group, the presence of an aca-
demic hospital, the discounted price per DDD of infliximab/
biosimilar/originator, the relative/absolute difference in dis-
counted price between the biosimilar and originator product, 
and the geographical location. Models were compared using 
Fig. 1  Organisation of and key players involved in the hospital (top) 
and outpatient setting (bottom) in Sweden [44]. Reproduced with per-
mission from Gustaf Befrits. NT-Council New Therapies Council, 
TLV Tandvårds- och läkemedelsförmånsverket (Dental and Pharma-
ceutical Benefits Agency)
288 E. Moorkens et al.
the adjusted determination coefficient (R2), accounting for 
multicollinearity and the authors’ knowledge of the Swedish 
healthcare system.
2.3  Interviews
We conducted follow-up interviews with local correspond-
ents to discuss the results of the comparative analysis and 
to gain more in-depth information to add to the analysis. 
First, discussions were held with the national pricing and 
reimbursement agency (The Dental and Pharmaceutical 
Benefits Agency) and one county council (Stockholm). 
Subsequently, local interviews were conducted with five 
county representatives in Skåne, Västra Götaland, and 
Stockholm. These counties were selected based on previ-
ous analysis of literature and market data; combined, they 
represent > 50% of the Swedish population. County coun-
cils were contacted via email or telephone to ask whether 
they could refer us to their biosimilar expert for a discus-
sion on how they approach biosimilars in their county. In 
addition, one interview was conducted with an industry 
representative to get a more comprehensive view of market 
dynamics in the different counties in Sweden. An interview 
guide was used to structure the interviews. Questions were 
based upon the comparative analysis of relevant literature 
and market data and discussions with the national pricing 
and reimbursement agency and were organised into two 
topics: general questions on the county’s policy on bio-
similars and questions on the market data for infliximab. 
All interviewees received an email with an informed con-
sent form to ask permission to record the interviews for 
data analysis. All interviews were conducted face to face 
in Sweden, in English, in March 2018. The recorded inter-
views were transcribed ad verbatim, coded, and processed 
using qualitative analysis. Results from the interviews 
were verified with the national pricing and reimbursement 
agency, and any outstanding questions about the Swedish 
healthcare system and observations during the interviews 
were further explored.
3  Results
3.1  Market Data for Infliximab in All Counties
The market share of biosimilar infliximab ranges widely 
across Sweden (based on volume), from 18% in Västman-
land to 96% in Gotland in 2017. Table 1 shows biosimilar 
market shares over time for the different Swedish counties. 
In quarter four of 2017, two groups of counties can be dis-
tinguished: counties with biosimilar market shares of ≥ 70% 
and those with market shares of ≤ 50%. Biosimilar market 
shares over time for the counties show that initial uptake 
of biosimilar infliximab was slow and varied widely, with 
abrupt increments in biosimilar market shares. This is due 
to the procurement mechanism for infliximab, where coun-
ties might have initially still been locked into a contract for 
the originator product,  Remicade®.
Table 1  Market shares (%) of biosimilar infliximab over time for the different Swedish counties. Colours gradually change from red to green 
with increasing biosimilar market shares
County 2015 Q1 2015 Q2 2015 Q3 2015 Q4 2016 Q1 2016 Q2 2016 Q3 2016 Q4 2017 Q1 2017 Q2 2017 Q3 2017 Q4
Blekinge 15% 23% 24% 21% 23% 20% 33% 59% 74% 76% 76% 77%
Dalarna 0% 5% 1% 6% 5% 11% 12% 13% 15% 34% 67% 87%
Gävleborg 0% 0% 0% 2% 0% 14% 5% 25% 31% 42% 46% 50%
Gotland 0% 0% 5% 20% 4% 25% 13% 21% 98% 98% 96% 94%
Halland 0% 8% 8% 43% 66% 61% 62% 66% 77% 85% 84% 87%
Jämtland 0% 2% 0% 7% 19% 16% 13% 91% 90% 85% 94% 91%
Jönköping 0% 0% 1% 3% 3% 3% 5% 9% 37% 88% 84% 90%
Kalmar 4% 9% 5% 5% 5% 7% 5% 8% 34% 68% 66% 73%
Kronoberg 0% 6% 7% 17% 36% 79% 94% 84% 85% 84% 82% 81%
Norrbotten 0% 1% 2% 5% 11% 6% 6% 59% 80% 92% 91% 92%
Örebro 0% 0% 6% 16% 20% 39% 55% 58% 62% 81% 88% 89%
Östergötland 2% 6% 9% 17% 14% 15% 16% 23% 30% 33% 33% 36%
Skåne 2% 8% 19% 53% 72% 84% 87% 88% 89% 88% 90% 92%
Södermanland 0% 1% 7% 13% 30% 90% 92% 91% 89% 91% 90% 90%
Stockholm 0% 3% 6% 17% 18% 21% 23% 23% 80% 84% 87% 86%
Uppsala 0% 1% 1% 5% 6% 7% 8% 8% 16% 20% 22% 25%
Värmland 1% 7% 12% 23% 93% 90% 89% 90% 88% 89% 85% 88%
Västerbotten 0% 0% 8% 7% 3% 7% 8% 71% 94% 90% 88% 91%
Västernorrland 0% 0% 0% 5% 3% 6% 12% 78% 85% 86% 84% 83%
Västmanland 0% 1% 4% 7% 5% 5% 8% 15% 16% 15% 20% 23%
Västra Götaland 0% 2% 2% 9% 8% 11% 10% 16% 22% 41% 42% 47%
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Simple linear regression analysis of data from 2017 
revealed that 59% of the variability in biosimilar market 
shares between Swedish counties was explained by the rel-
ative difference in discounted price between the biosimilar 
and the originator product (p ≤ 0.001). Multiple regression 
models combining the relative difference in cost with other 
independent variables were analysed but did not further 
explain the variations. Furthermore, a logit transformation 
of the outcome variable (biosimilar market share) did not 
influence the check of assumptions or results.
A linear relationship provides a reasonable approxima-
tion when examining the scatterplot of the biosimilar market 
share and the relative difference in discounted price between 
the biosimilar and the originator product (Fig. 2), although 
other relationships may be applicable. However, building a 
predictive model was not the purpose of this study, rather 
it was to demonstrate the influence of the primary driver. 
When visually analysed, a positive non-linear relation-
ship can be seen, where the biosimilar market share rises 
when the relative difference in discounted price per DDD 
of the biosimilar versus the originator product in a county 
increases. This relationship then reaches a maximum: 
biosimilar market shares in counties exceed 76% from a 
threshold of a 40% difference in discounted price per DDD 
or more. When plotted as the absolute price difference, a 
difference of 50 Swedish kronor (SEK) per DDD (~ €5 per 
DDD) led to high biosimilar market shares (76–96%).
In addition to biosimilar market shares, we also analysed 
discounted prices per DDD. In quarter four of 2017, the 
discounted price per DDD of the originator ranged from 
SEK59 per DDD in Västra Götaland to SEK191 per DDD in 
Stockholm. The discounted price per DDD of the originator 
increased in Stockholm in quarter one of 2017, after loss of 
the single-winner tender on infliximab. In Västra Götaland, 
the originator product was priced at the same price level as 
the biosimilar. In 2017, a larger variation between counties 
was observed in the discounted price per DDD of the origi-
nator product (SEK69–190 per DDD) than for the biosimilar 
(SEK59–83 per DDD).
The average discounted price per DDD of infliximab in 
all counties decreased from SEK202 per DDD in 2012 to 
SEK173 per DDD in 2014 (the year before the entry of the 
biosimilar) and to SEK76 per DDD in 2017. Overall, in Swe-
den, the volume of infliximab (DDDs) increased 54% from 
quarter two of 2012 to quarter four of 2017 (compound annual 
growth rate of 8%), with more rapid escalation after the entry 
of the biosimilar in quarter one of 2015 (Fig. 3). Interview-
ees indicated that the increase in volume of infliximab could 
possibly be attributed to a lower threshold at which treatment 
is initiated (due to elimination of the price obstacle but also 
fewer concerns about the safety of biologicals now they have 
been on the market for some time), increased dosing now that 
prices have decreased, and more treatment-naïve patients 
receiving products for which a biosimilar exists. In Skåne, 
treatment of a patient with an expensive medicine requires 
Fig. 2  Scatterplot of market shares of the infliximab biosimilar in the 21 Swedish counties in 2017 (outcome variable) and the relative difference 
in discounted price per defined daily dose (DDD) of the biosimilar relative to the originator product (covariate)
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consensus from two physicians. Lowered prices can therefore 
lead to increased autonomy in prescribing.
3.2  Local Policy Measures and Practices 
in a Selection of Counties
3.2.1  General Observations on the Swedish Healthcare 
Market
TNFα inhibitors are available to patients in all counties, but 
differences might be seen in the threshold of initiation of 
therapy with biological medicines [7]. TNFα inhibitors are 
mainly prescribed by specialists, e.g. rheumatologists, der-
matologists and gastroenterologists, who also bear respon-
sibility for switching from the originator biological to the 
biosimilar [9]. On a national level, no pressure has ever been 
applied to switch between originator and biosimilar prod-
ucts. Reimbursement criteria are more binding, but adher-
ence to these criteria is not checked with the individual 
counties. In general, physicians in Sweden accept biosimi-
lars and have now accepted that the first switch is fine.
During the interviews, we observed that physicians in 
Sweden seem to have an altruistic attitude and are aware of 
cost increases with innovative medicines. To begin with, this 
might be a consequence of the perceived high level of trust 
that Swedish physicians have of the European Medicines 
Agency and the healthcare system in Sweden. In addition, 
this altruistic attitude may be enabled by the way the health-
care system is organised in relatively small regions, where 
you can see how the money saved is used in other thera-
peutic areas, and the relatively low number of specialists in 
an area allows good communication on new guidelines and 
market dynamics. In Skåne, rheumatologists were advised 
of the county council’s decision to switch all patients receiv-
ing the originator product to the biosimilar, and the deci-
sion was explained. Furthermore, prescribing behaviour was 
monitored to check whether recommendations were followed 
(although they are not binding). Physicians were individually 
encouraged to adhere to the agreements.
It appeared that counties leverage biosimilars to lower 
drug costs and make room for other patients to access treat-
ment, thus focusing on sustainability and not just on savings. 
The priority for the drug budget is to make room for seg-
ments that are increasing more than others, e.g., oncology. 
It was acknowledged that more could be done in terms of 
competition and short-term savings but that this would prob-
ably upset physicians and patient organisations. Moreover, 
aggressive price competition may undermine the long-term 
sustainability of a competitive market.
Interviewees identified several drivers of the decision 
making around using originator or biosimilar infliximab, 
which can differ between counties and therefore affect 
regional variations. These drivers are the absolute/relative 
difference in discounted price between the originator and 
biosimilar, the opinion of key opinion leaders or the prefer-
ences of the clinic head, local guidelines and initiatives in 
the hospital, and whose budget is affected.
As the organisation of the local healthcare system, finan-
cial streams and the level at which you have budget respon-
sibilities differ between counties, it was difficult to determine 
who benefited from potential cost savings. Gainsharing, 
where savings are shared between the payer and the hospital 
or prescribing physician, was suggested as a factor influ-
encing market dynamics. In Skåne, Stockholm and Västra 
Götaland, savings that are made via leveraging competition 
of biosimilars stay within the drug budget. As budgets for 
hospital medicines are adjusted every year, it may be that, 
in the long term, the county councils benefit from savings. 
In Skåne, approximately half of the savings return to the 
hospital departments affected, e.g. for new products such as 
vedolizumab, and half can be used in other therapeutic areas. 
The hospital budget is adjusted to the predicted need. The 
interviewees felt loyal to the system as they always received 
the budget they needed when using it as efficiently as pos-
sible. In Stockholm, hospitals must pay for drugs used in 
Fig. 3  Volume evolution (in 
defined daily doses) of inflixi-
mab in Sweden from quarter 
two of 2012 to quarter four of 
2017
291Influence of Local Policy on Market Dynamics of Infliximab in Swedish Counties
the inpatient setting from their own budget and can keep 
savings for use in other departments. In Västra Götaland, 
savings would remain in the hospital in the short term but 
their budget may be decreased in the long term.
3.2.2  County Approaches to the Entry of Infliximab 
Biosimilars
Table 2 presents some characteristics of the infliximab mar-
ket in the interviewed counties. The intention of the various 
counties in the tender process is to achieve a low price per 
DDD of infliximab. Figure 4 shows the different approaches 
taken by counties identified during the local interviews, i.e., 
a rapid switch to the biosimilar (Skåne), a delayed switch to 
the biosimilar (Stockholm), or no switch to the biosimilar 
when a favourable price on the originator product could be 
obtained (Västra Götaland). These approaches led to dis-
counted prices for infliximab of SEK64, SEK78, and SEK59 
per DDD, respectively, with a national mean of SEK70 per 
DDD and a range of SEK59–106 per DDD, in quarter four of 
2017. In Stockholm, although the discounted price per DDD 
of the biosimilar is low (SEK59 per DDD) and the biosimilar 
market share is high (86%), the use of the high-priced origi-
nator in few cases has led to an overall discounted price per 
DDD of infliximab that is higher than in Skåne or Västra 
Götaland.
According to the interviewees, the main criterion for 
awarding a contract is the price of the biosimilar or origi-
nator, since these products will not differentiate in terms 
of injection equipment and other criteria such as guaran-
teed delivery and good manufacturing practices. The dura-
tion of a tender is usually 2 years with an option to extend. 
As physicians do not like to switch every year, they prefer 
the tender duration to be as long as possible. Contracts of 
shorter duration can also be agreed when market conditions 
are expected to change in the near future, such as with the 
introduction of a new competitor. Some counties offer ten-
ders in which companies can adjust prices during the tender 
Table 2  Selection of characteristics of the infliximab market in the interviewed counties. Figures for quarter four of 2017
Difference in discounted price/DDD: difference in discounted price per DDD of the biosimilar relative to the discounted price of the originator 
product in quarter four of 2017
DDD defined daily dose
County Tender with biosimilar Biosimilar 
uptake (%)
Difference (%) in 
discounted price/
DDD
Discounted price 
(SEK)/DDD cheapest 
product
Discounted price 
(SEK)/DDD 
infliximab
Skåne Multi-winner (July 2015):  Remsima® 
cheapest
92 − 47 60 64
Stockholm Single winner (Jan 2017):  Inflectra® cheap-
est
86 − 69 59 78
Västra Götaland Multi-winner (Feb 2017):  Inflectra® and 
 Remicade® same price
47 1 59 59
Fig. 4  Different approaches of interviewed counties (Skåne, Stockholm, Västra Götaland) to leverage competition from biosimilar infliximab
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duration. In all three interviewed counties, guidelines rec-
ommended that the most cost-effective treatment should be 
chosen when initiating treatment for a new patient.
In Skåne, since 2014 (before the biosimilar entered the 
market), naïve patients were increasingly initiated on inf-
liximab instead of other TNFα inhibitors. In early 2015, 
when biosimilars to infliximab were launched on the market, 
Skåne was locked in a contract with the originator product 
until July 2015. It was decided not to switch patients at that 
time but to start using the biosimilar in new patients. After 
6 months, when preliminary information became available 
on the NOR-SWITCH trial (a comparative trial between 
patients switched from originator infliximab to biosimilar 
infliximab, CT-P13, and patients who maintained treatment 
with originator infliximab, funded by the Norwegian Minis-
try of Health; full results were published in 2017 [26]) and 
after consultation with colleagues, physicians in the expert 
group on biologicals decided to switch patients from the 
originator product to the less expensive biosimilar to save 
money. Key opinion leaders in gastroenterology supported 
this and had personal connections with colleagues involved 
in the NOR-SWITCH study.
Stockholm was also locked in a contract for the origina-
tor product when biosimilar infliximab entered the market. 
The Stockholm county council decided to move slowly with 
the first infliximab biosimilars to gain experience and create 
trust among physicians and patients so as to move quicker 
on future biosimilars. Therefore, the existing contract on the 
originator product was extended for another 2 years (until 
January 2017). However, a decrease in the price of the origi-
nator product was agreed to reflect competition in the mar-
ket, and a clause was included in the contract that allowed 
restricted use of the biosimilar. During 2015–2016, while 
Stockholm was still in the tender contract with the origina-
tor product, uptake of the biosimilar was higher than first 
expected (23%).
Västra Götaland also had a contract for the originator 
product (from 2014 to January 2017) when biosimilar inf-
liximab was introduced to the Swedish market. Within the 
contract, there was room for using other similar products, 
and the drug and therapeutics committee recommended that 
up to one-third of new patients could start with a biosimilar, 
since  Remsima® was less expensive.
In a multi-winner tender in Skåne in July 2015, the bio-
similar was the least expensive product. In October 2015, 
the expert group on biological medicines strongly encour-
aged prescribing of the biosimilar, which translated into an 
increased volume of biosimilar infliximab. This quick uptake 
of the biosimilar was attributed to good connections between 
the different hospital departments and consultation with the 
rheumatology patient organisation. In Stockholm, more expe-
rience was initially gained with the biosimilar before a new 
tender was organised. In January 2017, a single-winner tender 
on infliximab was won by infliximab biosimilar  Inflectra®, and 
all patients were switched, increasing the biosimilar market 
share from 23% in quarter four of 2016 to 80% in quarter one 
of 2017. All involved stakeholders were included in making 
this decision. In February 2017, Västra Götaland issued a 
new tender with a view to gaining a low price on both the 
originator product and biosimilar infliximab.  Inflectra® was 
the least expensive product; however, as the price of the origi-
nator product was subsequently lowered to match that of the 
biosimilar, there has never been an economic incentive for 
switching. First, physicians in Västra Götaland were locked 
in the contract for the originator product, then the price of the 
originator and the biosimilar was the same; in addition, they 
were not in favour of switching in early 2017.
When the biosimilar was the least expensive product in the 
tender process, active switching of patients from the originator 
product to the biosimilar was initiated in Skåne and Stock-
holm. In Skåne, different approaches for the different thera-
peutic indications were apparent. In rheumatology, either the 
physician informed the patient of a switch in treatment or a let-
ter was given to the patient explaining what a biosimilar was, 
that it is as safe and effective as the originator, and what the 
savings would be used for (e.g. to switch back if some patients 
experienced problems with the biosimilar). Patients were then 
switched at the next appointment (approximately 6 weeks 
later). In gastroenterology, a letter was given to patients at the 
outpatient unit; after receiving it, patients could talk to a nurse 
or ask further questions to their physician. Most patients had 
a positive attitude towards this initiative and were immedi-
ately switched. Dermatology patients also received a letter at 
the hospital followed by an immediate switch. In Stockholm, 
all patients with an appointment in November or December 
2016 were told that they would receive the biosimilar dur-
ing the next visit (January 2017). In Västra Götaland, none 
of the patients were switched. Only new patients were started 
on the biosimilar to spread the risk of, for example, delivery 
problems over different products. Since the NOR-SWITCH 
study [26], physicians in Västra Götaland accept switching 
once in stable and well-informed patients but do not support 
multiple switching. A good incentive, such as a long-term sub-
stantial difference in price, would convince them to switch and 
overcome the associated administrative work. A good price on 
the originator product, as this was long their product of first 
choice, explains the limited use of infliximab biosimilars in 
Västra Götaland.
4  Discussion
Many publications only provide an overview of existing 
policy measures on biosimilars [27–29], therefore several 
authors recommended that the impact of implemented 
policies and practices be studied quantitatively [27, 30]. In 
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response, this article quantifies the relation between the bio-
similar market share and the net discount of the biosimilar 
relative to the price of the originator product. Furthermore, 
it provides a descriptive analysis of the evolution of market 
data of originator and biosimilar infliximab in the differ-
ent counties of Sweden. Clarification of trends observed 
in market dynamics was obtained from literature and from 
local interviews. Table 3 summarizes the identified drivers 
and enablers in the Swedish healthcare system to leverage 
competition from biosimilars. Both the quantitative and 
the qualitative study revealed that increasing differences 
in discounted price between the biosimilar and originator 
product would favour the use of the least expensive prod-
uct, indicating that potential savings associated with the bio-
similar would incentivise stakeholders to switch from the 
originator product to the biosimilar. In addition, preferences 
of key opinion leaders also play a role in decision making 
and implementation, as do local guidelines and how savings 
will be distributed among stakeholders. Enabling factors 
such as a multi-stakeholder approach, an altruistic attitude 
of prescribers and good communication between colleagues 
facilitates implementation of outcomes of tender contracts 
and guidelines. Earlier research also noted the influence of 
the altruistic attitude of the Swedish population on percep-
tions and behaviour [31, 32].
4.1  Added Value of This Study
To the best of our knowledge, this is one of the first studies 
to evaluate regional variations to study the effect of bio-
similar policies and initiatives on market dynamics, with 
Sweden and its counties as a case study. Neovius et al. [7] 
studied regional variations in Sweden for sales per capita of 
originator TNFα inhibitors. In contrast, our study includes 
competition by the introduction of biosimilars. Other stud-
ies also reported regional variations in biosimilar uptake in 
a country [9, 11, 13, 14] but did not explicitly link this to 
implemented policies or derived driving factors influenc-
ing the market dynamics of TNFα inhibitors. A study by 
Rémuzat et al. [33] followed a similar methodology to ours 
when they performed a regression model analysis based 
on a literature review of incentive policies and analysis of 
biosimilar market data in ten EU member states to iden-
tify drivers of biosimilar uptake in Europe. Our study on 
regional variations in one country, Sweden, combines a 
literature review and database analysis with face-to-face 
discussions to explain findings. Additionally, we used net 
prices for the hospital market, leading to substantially dif-
ferent outcomes. Our study indicated a strong relationship 
between the biosimilar market share and the net discount of 
the biosimilar relative to the price of the originator product, 
whereas Rémuzat et al. [33] found that the biosimilar listed 
price discount over the price of the originator product was 
not associated with biosimilar uptake. This emphasises the 
importance of working with actual prices rather than list 
prices in determining factors driving decision making.
4.2  Price Effects
This study also showed that biosimilars for infliximab cre-
ated competition in the infliximab market. Overall, we 
observed a decrease in the discounted price per DDD of inf-
liximab in all counties since the introduction of the biosimi-
lar and a concomitant increase in patients being treated with 
infliximab. This will benefit patients, as early treatment with 
biologicals will lead to improved clinical responses [34–36]. 
The price of a product plays a major role in choice of treat-
ment, as illustrated by high biosimilar market shares of inf-
liximab with increasing differences in the discounted price 
of the biosimilar relative to the originator product. In Västra 
Götaland, the market share of the biosimilar increased since 
its entry in quarter two of 2015 as a result of a lower price. 
As the price of the originator and biosimilar were set at the 
same level in February 2017, this leads us to expect that 
the biosimilar market share will not increase further during 
this tender period. Being the first biosimilar on the market 
will be an advantage, as it will be harder for subsequent 
biosimilars to match a similar absolute price difference with 
the product currently used in order to offer an incentive for 
counties to switch between biosimilars. It is unclear from 
this study what difference in price is needed to switch back 
from the biosimilar to the originator or to a second biosimi-
lar, as this could not be examined.
Table 3  Identified drivers and enablers in the Swedish healthcare system to leverage competition from biosimilars
DDD defined daily dose
Drivers Enablers
Quantitative study Qualitative study
The difference in discounted price per DDD between the bio-
similar and the originator product (potential savings)
The difference in discounted price per 
DDD
Key opinion leaders
Local guidelines
Gainsharing
A multi-stakeholder approach
An altruistic attitude
Good communication with colleagues
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4.3  Competition and Market Sustainability
It has been illustrated that lowering drug costs is not just 
about uptake of the biosimilar but also about leveraging 
competition to alter market dynamics between biosimilar 
and originator products, and associated prices. The differ-
ent tender groups in Sweden make the market sustainable 
for both originator and biosimilar infliximab. On the one 
hand, tenders being organised at a county level offers an 
advantage in that a manufacturer who does not win the bid 
in one county has an incentive to stay on the market by par-
ticipating in tenders in other counties. On the other hand, the 
limited market size of individual counties may restrict the 
price reductions offered by manufacturers in contrast with 
national tenders (such as, for example, in Norway [37]). A 
concern related to the tender system is the sustainability of 
discounts. Although all counties want a large reduction in 
price, if prices are pushed to the limit, there is a risk that 
companies will withdraw their product from the market.
In contrast to Sweden, where existing contracts can hin-
der market access of biosimilars, the Italian procurement law 
of December 2016 established a new framework for procure-
ment of off-patent biological products. In this framework, 
based on therapeutic equivalence, biosimilars and originator 
products will compete in the same tender [38]. Regional 
health authorities must open existing contracts within 
60 days after launch of the biosimilar to create competition 
[39]. When more than three competitors are on the market, 
a multi-winner regional tender is organised, after which 
physicians must prescribe one of the top three preferred 
products, except when they deem treatment of the patient 
should not be interrupted. This system allows immediate and 
direct competition between biosimilars and originator prod-
ucts, with promotion of the least expensive products, while 
maintaining physicians’ prescribing freedom. However, an 
advantage of the Swedish system is the increased autonomy 
in making decisions on a new tender, allowing the opinions 
of all stakeholders on the use of biosimilars and switching 
from the originator to the biosimilar to be aligned first.
4.4  Influences on Prescribing Behaviour 
of Specialists
The current thinking of Swedish specialists prescrib-
ing TNFα inhibitors seems to be in line with the position 
statement of the Swedish Medical Products Agency, which 
deems treatment with a biosimilar uncontroversial in treat-
ment-naïve patients and believes no barriers exist to switch 
stable, well-informed patients from the originator biologi-
cal to the biosimilar [9, 40]. The position statement also 
indicates that more data are needed on multiple switching. 
To provide information from independent third parties, the 
Dental and Pharmaceutical Benefits Agency and the Medical 
Products Agency combined efforts to educate stakeholders 
[9]. However, as national authorities can only recommend 
but the individual counties decide which products to use, 
this might undermine the objective of providing equal care 
to patients [15, 16].
On the other hand, decentralising the responsibility for 
providing healthcare to the county councils has the advan-
tage that specialists and other healthcare professionals often 
know each other and therefore tend to follow recommen-
dations quicker than if a national organisation announces 
guidance on prescribing. It has been shown that activities 
of the kind performed by the drug and therapeutics commit-
tees have more impact on prescribing patterns when organ-
ised at a local level and built on personal relations [10]. 
An increased awareness by stakeholders on the use of taxes 
might have contributed to the system of solidarity and the 
altruistic attitude of physicians towards using the savings in 
other therapeutic areas.
4.5  Verification of Identified Drivers
Earlier research on uptake of new medicines also identi-
fied the importance of communication between colleagues 
and the influence of key opinion leaders [41, 42]. Chauhan 
et al. [41] concluded that the impact of clinical guidelines on 
uptake of new medicines has been variable, possibly due to 
concerns of the evidence-based nature of the guidelines and 
a perceived loss of autonomy by physicians. Research on the 
high adherence of physicians to the recommendations of the 
Wise List in Stockholm, which also includes guidance on the 
use of TNFα inhibitors, explained that a transparent devel-
opment process and a multi-stakeholder approach including 
key opinion leaders is used to come up with sound evidence-
based prescribing guidance [25]. Other contributing factors 
that are mentioned are a good communication strategy, feed-
back to physicians, education and financial incentives.
Given that healthcare systems tend to be complex and 
vary between countries, it may not be possible to extrapo-
late our findings directly to other countries. However, we 
believe some general drivers can be identified that can be 
applied in other countries to support a sustainable biological 
market with competition from biosimilars. Where tendering 
is a factor related to the system, contextual factors can be 
more easily adapted. Introduction of guidance on prescribing 
and follow-up on adherence of these guidelines can be one 
measure. A drug utilisation study in a region in Italy showed 
that guidance on prescribing granulocyte colony-stimulating 
factors led to an increased uptake of the less expensive bio-
similar [43]. Other measures might be consultation between 
stakeholders, a focus on a multi-stakeholder approach in 
decision making and implementation, and the introduction 
of gainsharing arrangements. Furthermore, experts in their 
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field that push for the least expensive treatment option might 
trigger physicians to reflect on their prescribing behaviour.
4.6  Limitations
This study is subject to a number of limitations. First, we did 
not interview representatives from all 21 counties, impact-
ing the generalizability of outcomes for Sweden. As the 
three interviewed counties represent > 50% of the popula-
tion and > 50% of the use (volume) of infliximab, this will 
probably not considerably affect our results. Second, this 
study investigated only the biosimilar TNFα market, not 
the total biosimilar market. Also, no (biological) therapies 
other than TNFα inhibitors were considered for treatment of 
shared indications, e.g., abatacept, rituximab, tocilizumab. 
The largest shifts in market dynamics are expected to happen 
within the class of TNFα inhibitors. Third, regression analy-
sis can serve to determine the influence of one variable on 
the biosimilar market share or to explain as much of the vari-
ation as possible. Statistical reasons, i.e. a limited number 
of observations, correlation between independent variables, 
non-linearity of the data, led us to choose a model describ-
ing the primary driver, i.e. the difference in price between 
the biosimilar and the originator product, accounting for net 
prices instead of list prices.
4.7  Future Research
Future research could focus on regional variations in other 
European countries (e.g. Spain, Italy, Germany, the UK) to 
investigate whether the drivers identified in this study are 
also applicable to other healthcare systems. A regression 
model could then be developed with more universal drivers 
predicting a high or low biosimilar market share, and fac-
tors that lead to decreases in drug costs could be identified. 
Furthermore, factors affecting regional variations in Sweden 
in healthcare services provided to residents could be further 
investigated to streamline best practices.
5  Conclusion
This study has shown that variation in biosimilar inflixi-
mab market shares between Swedish counties is largely 
explained by the relative difference in discounted price 
between biosimilar and originator product. Visual inspec-
tion of the data suggests high uptake of the biosimilar 
upward of 40% difference in discounted price. Counties 
employed different strategies to leverage price reductions 
generated by biosimilar competition. The discounted price 
per DDD of infliximab reduced in all counties following 
market entry of biosimilars; this was achieved either with 
a lower price for biosimilar infliximab or with a large price 
reduction for the originator product consequent to biosimi-
lar competition.
Treatment costs associated with infliximab ranged 
from SEK59 to SEK106 per DDD in quarter four of 2017, 
implying that some counties employed more effective 
approaches than others to reduce prices. Factors influenc-
ing decision making may vary between counties, e.g. a 
large price difference between the biosimilar and the origi-
nator product, local guidelines and follow-up on adher-
ence, presence of key opinion leaders, a head of clinic 
who is strongly involved in the discussion, awareness of 
physicians on the high costs of biological treatment, and 
the possibility of keeping savings and using them to treat 
more patients or sustain budgets in other therapeutic areas. 
The success of these drivers should be seen in relation to 
the presence of enabling factors in the Swedish hospital 
setting, such as a multi-stakeholder approach, an altruistic 
attitude of prescribers, and good communication between 
specialists prescribing infliximab.
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